Zentalis Pharmaceuticals (ZNTL) Announces Proposed 3.75M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Zentalis Pharmaceuticals (ZNTL) Enters Pact Eli Lilly (LLY) to Evaluate its Oral SERD ZN-c5 in Combination with Abemaciclib, a CDK4 and 6 Inhibitor
July 27, 2020 7:04 AM EDTZentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a clinical collaboration agreement with Eli Lilly and Company (NYSE: LLY, Lilly) in which Zentalis will evaluate the combination of ZN-c5, the Companys oral selective estrogen receptor degrader (SERD) product candidate, and Verzenio® (abemaciclib), Lillys CDK4 and 6 inhibitor, in patients with ER+/HER2- advanced breast cancer.
This is a new,... More
